We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

131 hedge funds and large institutions have $254M invested in Catalyst Pharmaceutical in 2020 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 49 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

243% more call options, than puts

Call options by funds: $819K | Put options by funds: $239K

11% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 19

8% more capital invested

Capital invested by funds: $236M → $254M (+$18.3M)

2.78% more ownership

Funds ownership: 60.98% → 63.76% (+2.8%)

1% more funds holding

Funds holding: 130 → 131 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 49

Holders
131
Holders Change
+1
Holders Change %
+0.77%
% of All Funds
2.89%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
21
Increased
44
Reduced
49
Closed
19
Calls
$819K
Puts
$239K
Net Calls
+$580K
Net Calls Change
+$850K

Top Buyers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
+$11.5M
2
PVI
Pura Vida Investments
New York
+$5.94M
3
OM
Opaleye Management
Massachusetts
+$4.31M
4
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$4M
5
Millennium Management
Millennium Management
New York
+$3.29M

Top Sellers

Rank Fund Capital Flow
1
N
Nuveen
North Carolina
-$7.18M
2
Squarepoint
Squarepoint
New York
-$3.11M
3
Prudential Financial
Prudential Financial
New Jersey
-$3.04M
4
Two Sigma Investments
Two Sigma Investments
New York
-$2.87M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
-$2.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
MLICM
101
Metropolitan Life Insurance Company (MetLife)
New York
$77.5K +$16.7K +4,079 +25%
State Board of Administration of Florida Retirement System
102
State Board of Administration of Florida Retirement System
Florida
$76K -$903 -220 -1%
PMG
103
ProVise Management Group
Florida
$73K – – –
RJA
104
Raymond James & Associates
Florida
$72K -$34.5K -8,407 -31%
AWS
105
AJ Wealth Strategies
New York
$70K – – –
PAM
106
Panagora Asset Management
Massachusetts
$67K -$982K -239,171 -93%
Legal & General Group
107
Legal & General Group
United Kingdom
$66K -$17.8K -4,335 -20%
AB
108
Amalgamated Bank
New York
$66K +$279 +68 +0.4%
9WM
109
9258 Wealth Management
Ohio
$65K – – –
Commonwealth Equity Services
110
Commonwealth Equity Services
Massachusetts
$62K – – –
HS
111
HighVista Strategies
Massachusetts
$61K – – –
MAM
112
Meeder Asset Management
Ohio
$52K +$29.8K +7,255 +112%
Two Sigma Investments
113
Two Sigma Investments
New York
$50K -$2.87M -699,686 -98%
Lazard Asset Management
114
Lazard Asset Management
New York
$49K +$36.8K +8,960 +238%
Walleye Capital
115
Walleye Capital
New York
$46K +$49.3K +12,000 New
BCM
116
Bayesian Capital Management
New York
$46K +$49.3K +12,003 New
GWS
117
Glassman Wealth Services
Virginia
$44K – – –
HSA
118
HBK Sorce Advisory
Pennsylvania
$43K – – –
HighTower Advisors
119
HighTower Advisors
Illinois
$43K +$538 +131 +1%
CLOS
120
Compagnie Lombard Odier SCmA
Switzerland
$38K +$41K +10,000 New
AIP
121
Ameritas Investment Partners
Nebraska
$35K – – –
Zurich Cantonal Bank
122
Zurich Cantonal Bank
Switzerland
$27K – – –
Canada Life
123
Canada Life
Manitoba, Canada
$21K – – –
NIT
124
NumerixS Investment Technologies
British Columbia, Canada
$16K -$156K -37,900 -90%
SC
125
Stralem & Co
New York
$11K +$11.9K +2,900 New
2 3 4
5
6

CPRX Hedge Fund Activity: Q1 2020 in Review

131 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2020, worth a combined $254M — up 7.8% from $236M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new CPRX positions and 19 closed out — a net gain of 2 holders — while 44 added to existing stakes and 49 trimmed.

The largest buyer was Mangrove Partners, adding an estimated $11.5M. The largest seller was Nuveen, cutting an estimated $7.18M.

  • 131 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2020, up from 130 in Q4 2019.
  • Funds reported $254M of Catalyst Pharmaceutical stock for Q1 2020, up 7.8% quarter-over-quarter.
  • 21 funds opened new Catalyst Pharmaceutical positions in Q1 2020 and 19 closed out, a net change of +2 holders.
  • The largest Catalyst Pharmaceutical buyer in Q1 2020 was Mangrove Partners, an estimated $11.5M added.
  • The largest Catalyst Pharmaceutical seller in Q1 2020 was Nuveen, an estimated $7.18M sold.

Based on aggregated 13F filings for Q1 2020.